We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Synlogic Inc | NASDAQ:SYBX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.11 | 6.15% | 1.90 | 1.83 | 2.01 | 1.90 | 1.8045 | 1.86 | 7,713 | 01:00:00 |
– Presentation of full clinical data from first in-human study of Synthetic Biotic™ medicine expected in 1Q 2018 –
– IND for SYNB1020 for the treatment of hyperammonemia in patients with liver disease has been cleared by the FDA –
– Additional trials in patients with UCD and PKU expected to begin in 2018 –
Synlogic (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to probiotics to develop novel living medicines, today provided an overview of recent progress and outlined key objectives and anticipated milestones for 2018.
“For Synlogic, 2017 was a landmark year in which we made significant clinical progress with the completion of the first-in-human trial of our Synthetic Biotic platform,” said J.C. Gutiérrez-Ramos, Ph.D., Synlogic’s president and chief executive officer. “Importantly, this study in healthy volunteers provided the first ever demonstration of a dose-dependent effect on a systemic metabolite by an orally-administered living medicine which functions in the gut. We demonstrated that our Synthetic Biotic medicine was safe and well tolerated, and gained valuable experience in manufacturing, dosing and clinical evaluation of this new therapeutic modality. In 2018 we expect to present the full data from this study and further validate the platform with several clinical catalysts including the initiation of three clinical trials in our two lead programs for hyperammonemia and phenylketonuria.”
2018 Goals and Catalysts:
SYNB1020: An orally delivered, first-in-class, Synthetic Biotic medicine designed for treatment of elevated blood ammonia levels (hyperammonemia) in genetic urea cycle disorders (UCDs) or in chronic liver disease.
SYNB1618: An orally delivered, Synthetic Biotic medicine designed for the treatment of phenylketonuria (PKU)
Pre-clinical data and early pipeline programs
Corporate
2017 Accomplishments and Highlights:
SYNB1020:
SYNB1618:
Corporate
About Synthetic Biotic MedicinesSynlogic’s innovative new class of Synthetic Biotic medicines leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company’s two lead programs target a group of rare metabolic diseases – inborn errors of metabolism (IEM). Patients with these diseases are born with a faulty gene, inhibiting the body’s ability to break down commonly occurring by-products of digestion that then accumulate to toxic levels and cause serious health consequences. When delivered orally, these medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect. Synthetic Biotic medicines are designed to clear toxic metabolites associated with specific metabolic diseases and have the potential to significantly improve symptoms of disease for affected patients.
About SynlogicSynlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic’s initial pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as urea cycle disorders (UCD) and phenylketonuria (PKU). In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit www.synlogictx.com.
Forward-Looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic’s platform to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism, liver disease, inflammatory and immune disorders, and cancer; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; the potential of Synlogic’s technology to treat hyperammonemia and phenylketonuria; the expected timing of Synlogic’s anticipated clinical trial initiations; the advancement of our collaborations, and the benefit of orphan drug status. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in Synlogic’s filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic’s current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic’s view as of any date subsequent to the date hereof.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180105005195/en/
SynlogicMEDIA:Courtney Heath, 617-872-2462courtney@scientpr.comorINVESTORS:Elizabeth Wolffe, Ph.D., 617-207-5509liz@synlogictx.com
1 Year Synlogic Chart |
1 Month Synlogic Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions